0.6375
price up icon10.87%   0.0625
after-market Dopo l'orario di chiusura: .63 -0.0075 -1.18%
loading
Precedente Chiudi:
$0.575
Aprire:
$0.5788
Volume 24 ore:
12.92M
Relative Volume:
0.91
Capitalizzazione di mercato:
$230.45M
Reddito:
$1.21M
Utile/perdita netta:
$-177.12M
Rapporto P/E:
-0.7969
EPS:
-0.8
Flusso di cassa netto:
$-162.37M
1 W Prestazione:
+24.49%
1M Prestazione:
+75.52%
6M Prestazione:
-67.14%
1 anno Prestazione:
-62.72%
Intervallo 1D:
Value
$0.577
$0.6445
Intervallo di 1 settimana:
Value
$0.48
$0.6445
Portata 52W:
Value
$0.2836
$2.45

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
Nome
Lexicon Pharmaceuticals Inc
Name
Telefono
(281) 863-3000
Name
Indirizzo
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
Dipendente
103
Name
Cinguettio
@LexPharma
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
LXRX's Discussions on Twitter

Confronta LXRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LXRX
Lexicon Pharmaceuticals Inc
0.6375 230.45M 1.21M -177.12M -162.37M -0.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-05 Downgrade Leerink Partners Outperform → Market Perform
2024-06-17 Iniziato H.C. Wainwright Buy
2024-04-30 Iniziato Leerink Partners Outperform
2023-03-07 Iniziato Jefferies Hold
2022-08-12 Iniziato Piper Sandler Overweight
2021-01-29 Aggiornamento JP Morgan Underweight → Neutral
2021-01-29 Downgrade Wedbush Outperform → Neutral
2020-12-08 Aggiornamento Citigroup Neutral → Buy
2020-11-18 Aggiornamento Gabelli & Co Hold → Buy
2019-12-11 Downgrade Gabelli & Co Buy → Hold
2019-11-08 Downgrade Citigroup Buy → Neutral
2019-09-11 Aggiornamento Gabelli & Co Hold → Buy
2019-07-29 Downgrade Stifel Buy → Hold
2019-03-25 Aggiornamento Gabelli & Co Sell → Hold
2018-07-31 Reiterato Stifel Buy
2018-02-23 Downgrade Needham Buy → Hold
2018-02-14 Downgrade JP Morgan Neutral → Underweight
2017-03-01 Reiterato H.C. Wainwright Buy
2017-03-01 Reiterato Wedbush Outperform
2016-10-07 Iniziato H.C. Wainwright Buy
2016-08-05 Reiterato Wedbush Outperform
2016-08-02 Iniziato Citigroup Buy
2016-03-02 Reiterato Wedbush Outperform
2015-11-09 Reiterato Wedbush Outperform
2015-09-28 Aggiornamento Gabelli & Co Sell → Hold
2015-09-18 Downgrade Gabelli & Co Hold → Sell
2015-08-10 Downgrade JP Morgan Overweight → Neutral
Mostra tutto

Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie

pulisher
07:13 AM

Form ARS LEXICON PHARMACEUTICALS, For: Dec 31 - StreetInsider

07:13 AM
pulisher
Apr 09, 2025

Lexicon Pharmaceuticals at Needham Conference: Strategic Shift in Focus By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Novo Nordisk inks licensing pact with Lexicon for obesity candidate - MSN

Apr 09, 2025
pulisher
Apr 02, 2025

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Lexicon Pharmaceuticals to present at Healthcare Conference By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Lexicon Pharmaceuticals to present at Healthcare Conference - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Lexicon Pharma (LXRX) to Present at the 24th Annual Needham Virtual Healthcare Conference - StreetInsider

Apr 02, 2025
pulisher
Apr 01, 2025

Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Lexicon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:LXRX) - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Novo Nordisk gains rights to novel small molecule inhibitor - European Pharmaceutical Review

Mar 31, 2025
pulisher
Mar 31, 2025

Houston-area company inks massive $1B deal for weight-loss drug - Chron

Mar 31, 2025
pulisher
Mar 31, 2025

Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal - BioWorld MedTech

Mar 31, 2025
pulisher
Mar 31, 2025

US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst - Benzinga

Mar 31, 2025
pulisher
Mar 29, 2025

The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU

Mar 29, 2025
pulisher
Mar 29, 2025

Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize

Mar 29, 2025
pulisher
Mar 28, 2025

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 - Investor's Business Daily

Mar 28, 2025
pulisher
Mar 28, 2025

What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals - Fidelity

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s - MedCity News

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B - The Business Journals

Mar 28, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon (LXRX) Secures $1 Billion Deal with Novo Nordisk for Obe - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry - insights.citeline.com

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal - Reuters

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharmaceuticals: Strategic Partnerships and Pipeline Advancements Drive Buy Rating - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharma soars as it licenses LX9851 to Novo Nordisk - The Pharma Letter

Mar 28, 2025
pulisher
Mar 28, 2025

Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon inks $1 billion deal with Novo Nordisk for obesity drug By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon stock rises on Novo Nordisk licensing deal (LXRX) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care Stocks Steady Premarket Friday - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharmaceuticals (LXRX) Soars 95% on Novo Nordisk Licensi - GuruFocus.com

Mar 28, 2025
pulisher
Mar 28, 2025

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk in licensing deal with Lexiconcould pay up to $1 billion - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon inks $1 billion deal with Novo Nordisk for obesity drug - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851 - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851 - StreetInsider

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan

Mar 28, 2025
pulisher
Mar 27, 2025

Chronic Neuropathic Pain Market to Reach New Heights in Growth - openPR

Mar 27, 2025

Lexicon Pharmaceuticals Inc Azioni (LXRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
Capitalizzazione:     |  Volume (24 ore):